Stocktoria
EXAGEN INC. XGN
Nasdaq · stock · Services-Medical Laboratories · website · IPO 2019-09-19
EXAGEN INC. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $66.6M | $55.6M | $52.5M | $45.6M | $48.3M | $42.0M | $40.4M | $32.4M |
| Gross profit | $38.8M | $33.1M | $29.5M | — | — | — | — | — |
| R&D expense | $6.3M | $5.4M | $4.9M | $9.9M | $7.2M | $3.6M | $2.2M | $2.1M |
| SG&A expense | $46.6M | $41.4M | $47.4M | $52.0M | $44.5M | $37.0M | $28.7M | $19.7M |
| Operating income | -$14.1M | -$13.6M | -$22.8M | -$46.1M | -$24.1M | -$15.2M | -$9.3M | -$4.9M |
| Interest expense | — | — | $2.3M | $2.4M | $2.6M | $2.6M | $3.5M | $2.9M |
| Income tax | $51,000 | $12,000 | $33,000 | -$282,000 | $175,000 | -$79,000 | $25,000 | $58,000 |
| Net income | -$20.0M | -$15.1M | -$23.7M | -$47.4M | -$26.9M | -$16.7M | -$12.0M | -$8.0M |
| EPS (diluted) | $-0.93 | $-0.83 | $-1.34 | $-2.77 | $-1.68 | $-1.32 | — | — |
| Operating cash flow | -$13.6M | -$13.3M | -$14.5M | -$32.1M | -$20.3M | -$14.1M | -$9.7M | -$9.3M |
| Free cash flow | -$14.3M | -$13.8M | -$15.3M | -$36.5M | -$22.6M | -$14.5M | -$10.1M | -$9.5M |
| Cash & equivalents | $32.2M | $22.0M | $36.5M | $62.4M | $99.4M | $57.4M | $72.1M | $13.2M |
| Total assets | $58.0M | $44.7M | $56.9M | $86.2M | $123.4M | $78.4M | $88.3M | $28.9M |
| Total liabilities | $40.6M | $35.1M | $34.2M | $43.8M | $38.5M | $36.5M | $32.7M | $35.6M |
| Shareholders' equity | $17.4M | $9.5M | $22.7M | $42.5M | $84.9M | $41.8M | $55.7M | -$112.0M |
Growth · year-over-year · Revenue CAGR 10.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | +19.7% | +5.9% | +15.3% | -5.7% | +15.1% | +3.9% | +24.5% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.